萘呋胺酯治疗晚期人类乳腺癌的临床研究。
A clinical study of nafazatrom in advanced human breast cancer.
作者信息
Jones A L, Powles T J, Forgeson G V, Coombes R C
机构信息
Royal Marsden Hospital, Institute of Cancer Research, Sutton, Surrey, UK.
出版信息
Cancer Chemother Pharmacol. 1991;27(4):326-8. doi: 10.1007/BF00685120.
Prostaglandins (PGs) have been shown to inhibit tumour metastases in experimental animal systems. Nafazatrom is a pyrazolinone derivative that increases endogenous prostacyclin (PGI2) and has experimental anti-cancer activity. In the present study, nafazatrom was given to 47 women with advanced breast cancer; objective remission of metastases was seen in 2 patients and stabilisation of disease in 1 case. Nafazatrom was safe and well tolerated.
前列腺素（PGs）已被证明在实验动物系统中可抑制肿瘤转移。萘呋胺酯是一种吡唑啉酮衍生物，可增加内源性前列环素（PGI2），并具有实验性抗癌活性。在本研究中，对47例晚期乳腺癌女性患者给予萘呋胺酯治疗；2例患者出现转移灶客观缓解，1例患者病情稳定。萘呋胺酯安全且耐受性良好。
Zotero 插件